Peptides used in lowering the level of LDL in plasma when treating familial hypercholesterolemia.
- Author:
Lu SUN
1
;
Yilun YUE
;
Xixun YU
Author Information
1. Department of Polymer Science and Materials, Sichuan University, Chengdu 610065.
- Publication Type:Journal Article
- MeSH:
Adsorption;
Drug Carriers;
Drug Design;
Female;
Hemoperfusion;
instrumentation;
methods;
Humans;
Hyperlipoproteinemia Type II;
blood;
therapy;
Ligands;
Lipoproteins, LDL;
blood;
isolation & purification;
Male;
Peptides;
chemical synthesis;
therapeutic use;
Receptors, LDL;
chemistry
- From:
Journal of Biomedical Engineering
2003;20(2):336-339
- CountryChina
- Language:Chinese
-
Abstract:
While introducing the indications of low-density lipoprotein (LDL) apheresis, LDL absorption systems were reviewed generally. As the key components for binding LDL, four kinds of ligands which are synthesized by different principles are: 1. Positively charged peptides designed according to state charge force between ligand and LDL; 2. Peptides designed according to structural characteristics of the binding site between LDL and its receptors; 3. Antibody of Lp (a) obtained by immunizing mammals with designed peptides with the characteristics of Lp (a); 4. Segments of LDL binding proteins (LBPs) synthesized with genetic engineering method based on the specific binding of LBPs to LDL. Requirements of matrices carrying these ligands are also considered. Finally, future developments in treatments of familial hypercholesterolemia by means of blood purification using synthesized peptides are overlooked.
